Cell and gene therapy manufacturing scale-up/ scale-out

CELL AND GENE THERAPY INSIGHTS

September 2022

Cell and gene therapy manufacturing scale-up/ scale-out

Download PDF

Editorial

De-risking late-stage activities by retaining your early-stage expertise

De-risking late-stage activities by retaining your early-stage expertise

Nolan Sutherland

Expert Insight

Stabilizing DNA–PEI complexes improves scalability of suspension lentiviral viral vector and AAV processes

Stabilizing DNA–PEI complexes improves scalability of suspension lentiviral viral vector and AAV processes

B Olden, H Seo, R Barnes et al.

Innovator Insight

Manufacturing NK cells for the clinic: the Spanish experience

Manufacturing NK cells for the clinic: the Spanish experience

Antonio Pérez-Martínez, Marty Giedlin, Mariam Ammari

14 December 2022

Process development optimization for GMP manufacturing: a CAR-T case study

Process development optimization for GMP manufacturing: a CAR-T case study

12 December 2022

Achieve significantly increased adenovirus yield with density gradient ultracentrifugation: a comparative study

Achieve significantly increased adenovirus yield with density gradient ultracentrifugation: a comparative study

Shawn Sternisha

19 October 2022

Optimizing cell proliferation and function for immunotherapy with recombinant growth factors and cytokines

Optimizing cell proliferation and function for immunotherapy with recombinant growth factors and cytokines

18 September 2022

Accelerating cell therapy discovery & development with non-viral gene engineering

Accelerating cell therapy discovery & development with non-viral gene engineering

Xiaobai Patrinostro, David Hermanson, Scott Silaika

12 September 2022

Optimizing E. coli cell growth performance with in-line, real-time OD600 (abs/mm) monitoring during the fermentation process

Optimizing E. coli cell growth performance with in-line, real-time OD600 (abs/mm) monitoring during the fermentation process

Tanja Buch, Ramsey Shanbaky

Interview

De-risk & accelerate the drug development process for gene therapy

De-risk & accelerate the drug development process for gene therapy

22 September 2022

Making the switch from autologous to allogeneic cell therapy

Making the switch from autologous to allogeneic cell therapy

Elena Matsa, Andy Holt

11 September 2022

Collaboration, technology & innovation in the scale-up of viral vector manufacturing

Collaboration, technology & innovation in the scale-up of viral vector manufacturing

Matthias Hebben

2 September 2022

Mentoring new talent in the cell and gene therapy manufacturing sphere

Mentoring new talent in the cell and gene therapy manufacturing sphere

2 September 2022

Beginning with the end in mind: how early plasmid design and CDMO partnership can set you up for success in cell or gene therapy manufacturing

Beginning with the end in mind: how early plasmid design and CDMO partnership can set you up for success in cell or gene therapy manufacturing

Richard Parker-Manuel, Qian Liu

FastFacts

Off-the-shelf lentiviral vector packaging plasmids

Off-the-shelf lentiviral vector packaging plasmids

Tailor your cell culture platform to achieve your research objectives & scale requirements

Tailor your cell culture platform to achieve your research objectives & scale requirements

4 November 2022

Alleviate crucial challenges in scaling up gene therapy manufacturing

Alleviate crucial challenges in scaling up gene therapy manufacturing

11 September 2022

Key benefits of a microfluidic platform for cell culture at a clinically relevant scale

Key benefits of a microfluidic platform for cell culture at a clinically relevant scale

James Kusena, Mohsen Shaeri, Pedro Costa

10 September 2022

Digital data transformation: optimizing CGT processes and accelerating scale-up & tech transfer for manufacturing success

Digital data transformation: optimizing CGT processes and accelerating scale-up & tech transfer for manufacturing success

8 September 2022

Poster

Successful suspension-based viral vector manufacturing scale-up from process development to clinic

Successful suspension-based viral vector manufacturing scale-up from process development to clinic

D Kole, T P Cripe, L Giannunzio et al.

7 December 2022

De-risk and accelerate the drug development process for gene therapy

De-risk and accelerate the drug development process for gene therapy

29 September 2022

Webinars

Overcoming quality and regulatory challenges to reliably take your cell & gene therapy to commercialization

Overcoming quality and regulatory challenges to reliably take your cell & gene therapy to commercialization

Andreas Wirth, Christoph Meyer

15 September 2022

Scaling up an AAV production platform to support clinical and commercial needs: challenges and opportunities

Scaling up an AAV production platform to support clinical and commercial needs: challenges and opportunities

I Iwuchukwu, T Cunningham, A Becerra

20 September 2022

Overcoming contamination risks in cell and gene therapy with aseptic GMP process design using isolator technology

Overcoming contamination risks in cell and gene therapy with aseptic GMP process design using isolator technology

Chris Berridge, Donald Singer

22 September 2022

Feeder free expansion and closed wash and concentration of a clinically relevant number of human NK cells

Feeder free expansion and closed wash and concentration of a clinically relevant number of human NK cells

Erica Heipertz PhD

29 September 2022

Process development optimization for GMP manufacturing: A CAR-T case study

Process development optimization for GMP manufacturing: A CAR-T case study

Gary Pigeau PhD